CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges

Mayur Narkhede¹, Amitkumar Mehta¹, Stephen M. Ansell², Gaurav Goyal¹^*

¹Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL, USA; ²Division of Hematology, Mayo Clinic, Rochester, MN, USA

Contributions: (I) Conception and design: G Goyal, M Narkhede; (II) Administrative support: None; (III) Provision of study material or patients: None; (IV) Collection and assembly of data: M Narkhede; (V) Data analysis and interpretation: G Goyal, M Narkhede; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Gaurav Goyal. Division of Hematology-Oncology, University of Alabama at Birmingham, 1802 6th Avenue South Suite 2555 NP, Birmingham, AL 35294, USA. Email: ggoyal@uabmc.edu.

Abstract: The advent of chimeric antigen receptor T-cell (CAR T-cell) therapy has revolutionized the treatment paradigm of various hematologic malignancies. Ever since its first approval for treatment of acute lymphoblastic leukemia (ALL) in 2017, CAR T-cell therapy has been found to be efficacious in various other lymphoid malignancies, with recent approvals in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Although CAR T-cell therapeutics offer a novel immunotherapeutic approach to treat otherwise refractory malignancies, the plethora of studies/products and complexities in manufacturing and administration have led to several challenges for clinicians and the healthcare system as a whole. Some of the areas of unmet need include manufacturing delays, short persistence of CAR T-cells in circulation, lack of predictive biomarkers for efficacy and toxicity, and high cost of therapy. In this review, we evaluate the existing data on the efficacy and safety of CAR T-cell therapies in mature lymphoid malignancies [lymphomas, chronic lymphocytic leukemia (CLL), and multiple myeloma]. We also provide an in-depth review of the challenges posed by CAR T-cell therapeutics and potential strategies to overcome them. With newer CAR T-cell products and incorporation of measures to mitigate toxicities pertaining to cytokine release and neurological syndromes, there is a potential to overcome several of these challenges in the near future. Finally, as CAR T-cell therapy gains regulatory approval for more indications, there is a need to tackle the financial toxicity posed by this modality to sustain patient access.

Keywords: Lymphoma; myeloma; cost; toxicities; Hodgkin; mantle; chronic lymphocytic leukemia (CLL)

doi: 10.21037/atm-20-5546
View this article at: http://dx.doi.org/10.21037/atm-20-5546

Introduction

Although numerous advances have been made in harnessing the immune system to specifically target tumor cells, none have possibly been as promising and exciting as chimeric antigen receptor T-cell (CAR T-cell) therapy. CAR T-cells are genetically engineered T-cells consisting of a synthetic tumor antigen recognizing T-cell receptor (TCR) with the ability to mount a T-cell mediated antitumor effect (1-3).

The existing CAR T-cell constructs consist of three components; antigen recognition receptor, a hinged transmembrane domain, and an intracellular signal-
transducing domain (Figure 1). The antigen recognition receptor is composed of a single-chain variable fragment (scFv) consisting of heavy and light chains of a monoclonal antibody directed against an antigen. The scFv is linked to an intracellular signal-transducing domain by a hinged transmembrane domain. The hinged domain consists of sequences derived from IgG4 and CD8 domains. The intracellular domain contains the cytoplasmic tail of CD3-zeta (CD3ζ chain), functioning as a signal-transducing domain. The first generation CAR T-cell contains a single transducing domain, CD3. Second generation CAR T-cell constructs, in addition to the signal transducing domain, contains a co-stimulatory domain consisting of either 4-1BB or CD28. Third generation construct has both CD28 and 4-1BB co-stimulatory domains in addition to CD3. The fourth generation CAR T-cell constructs are engineered to release a transgenic cytokine upon CAR signaling in the targeted tumor tissue.

The second generation of CAR T-cells contained additional costimulatory molecules such as CD28, CD137/4-1BB, ICOS, or OX40.

Since the first iteration of CARs, newer methods in molecular biology have led to the construction of more effective second generation CARs, leading to regulatory approvals in lymphoid malignancies including acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

Mature lymphoid neoplasms are a heterogeneous group of disorders, ranging from indolent to aggressive lymphomas. They also include multiple myeloma, which is a neoplasm of terminally differentiated B-cells. Although the survival of various B-cell lymphomas has improved after introduction of rituximab-based immunochemotherapy, numerous areas of unmet need persist. In the most common subtype of aggressive lymphomas, DLBCL, the median overall survival for primary refractory disease is about 6 months (5). However, poor prognosis has also been reported among other B-cell lymphomas and multiple myeloma, especially in the setting of primary refractory disease, early relapse, or relapse after multiple lines of therapy (6-8). Although the use of immunotherapy by utilizing immune checkpoint inhibitors has been revolutionary in various malignancies, the response rates
in lymphoid neoplasms beyond classic Hodgkin lymphoma (HL) have been low. Harnessing of host immunity by utilizing CAR T-cell therapy offers a novel and rational treatment approach to target this patient population. In this review, we focus on the existing data using CAR T-cell therapy in mature lymphoid neoplasms, associated challenges, and potential strategies to overcome them.

**CAR-T cells in clinics**

**Early clinical development of CAR-T cells**

With successes in preclinical studies, first in human trials were initially conducted in solid tumors targeting diasialoganglioside GD2 in neuroblastoma, α-folate receptor (FR) in ovarian cancer, and carboxy-anhydrase-IX (CAIX) antigen in renal cell carcinoma (9-11). These first-generation CAR T-cell constructs did not persist in large numbers for the long-term, leading to short term responses. Also, toxicities were observed due to the sharing of antigens on tumor cells and healthy cells, as seen with the anti-CAIX CAR T-cell construct with the sharing of the CAIX antigen between renal cell carcinoma cells and normal bile duct epithelium (11). Successful clinical use of CAR T-cells required a targetable antigen overexpressed on tumor cells with minimal off-target effects and a costimulatory domain necessary for persistence of CAR T-cells.

**CAR-T cells in non-Hodgkin lymphoma (NHL)**

CD19 is a transmembrane protein with its expression specific to the B-cell lineage of lymphocytes. It is present from the early stages of pre-B-cell development until terminal differentiation into plasma cells (12). Being a B-cell lineage surface marker, CD19 is expressed on the majority of NHL, ALL and chronic lymphocytic leukemia (CLL) cells (13). The most notable clinical use of CAR T-cell therapy has been in B-cell malignancies. Carl June and his colleagues designed an anti CD19 CAR T-cell coupled with 4-1BB (a costimulatory receptor in T cells ) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains (14). This second-generation anti CD19 CAR T-cell was infused in patients with CD19 expressing refractory CLL. The CAR T-cells expanded 1,000 times the initial concentration, tracked to the bone marrow and lymph nodes, and achieved deep and durable responses lasting up to 4 years (15). Similarly, CAR T-cells were also studied in other CD19+ NHLs.

Axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are the three different CAR T-cell therapies studied in relapsed/refractory DLBCL with impressive ORR rates and durable responses (Table 1). Axi-cel and Tisa-cel are US Food and Drug Administration (FDA) approved for the treatment of DLBCL in second or later relapses. Recently, FDA has also approved brexucabtagene autoleucel (also known as KTE-X19) for relapsed/refractory MCL based on impressive ORR rates and durable responses (Table 1).

CD19-CAR T-cell therapy has also been evaluated in CLL and follicular lymphoma and are awaiting approval from the FDA for its use in these indications (Table 2) (15-22). CD20 is another well-known target for B-cell NHLs, with some responses noted in initial studies (23). More recently, tandem bispecific anti-CD20, anti-CD19 CAR T-cells have been evaluated for B-cell NHLs with 82% ORR and comparable safety to other products (24).

**CAR T-cell therapy in HL and T-cell lymphoma**

Classic HL and anaplastic large T-cell lymphoma (ALCL) are characterized by overexpression of CD30 protein on the surface of malignant cells. There is limited expression of CD30 on normal cells (25). Brentuximab vedotin, is a drug-antibody conjugate which targets CD30 and has been approved by the FDA for the treatment of HL and ALCL (26). Therefore, CAR T-cells targeting CD30 were developed and studied in HL and ALCL. Compared to the encouraging results seen in B-cell ALL and DLBCL, there is little to report on the efficacy and safety of anti-CD30 CAR-T cell therapy (Table 3) (27-30). The immunosuppressive tumor microenvironment possibly leads to suboptimal responses in HL. Therefore, a clinical trial evaluating the use of PD1 inhibitors after CD30 CAR T-cell is ongoing (NCT04134325). The use of CAR T-cells in HL is still in its infancy and will need better CAR constructs or combination therapy for its successful use in the clinic.

T-cell lymphomas are a heterogeneous group of malignancies of the T-cell origin. The following challenges have made it difficult for utilizing the benefits of CAR T-cell therapy in T-cell lymphomas. With the sharing of the antigens between malignant T-cells and CAR T-cells, concerns of fratricide arise. B-cell aplasia, which is seen after CD19 CAR T-cell therapy, is a common off-target/off tumor effect observed which requires long-term immunoglobulin infusions. Similar T-cell aplasia, if observed, can lead to severe immunodeficiency with
increased incidence of severe opportunistic infections. Also, CAR transduction of malignant cells during autologous generation of CAR T-cells can lead to rapid progression of T-cell lymphoma/leukemia. To overcome these barriers, CAR cells that target unique antigens need to be developed. CAR T-cells targeting CD7 and TCR beta constant 1 are currently being studied in early phase trials (NCT04004637, NCT03590574). Alternatively, CAR NK cells targeting CD5 are also being studied in early phase clinical trials (NCT03081910).

### CAR T-cell therapy in multiple myeloma

Despite the development of numerous novel agents in the past couple of decades in multiple myeloma, it remains an incurable disease. The plasma cells lack the expression of CD19, but have an overexpression of B-cell maturation antigen (BCMA). Although BCMA

Table 1 Phase 2 clinical trials of CAR T-cell therapy in DLBCL, mantle cell lymphoma and follicular lymphoma

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Axicabtagene Ciloleulcel (16)</th>
<th>Tisagenlecleucel (17)</th>
<th>Lisocabtagene Maraleucel (18)</th>
<th>Brexucabtage Autoleucel (19)</th>
<th>Axicabtagene Ciloleulcel (20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial</td>
<td>ZUMA-1</td>
<td>JULIET</td>
<td>TRANSCEND-001</td>
<td>ZUMA-2</td>
<td>ZUMA-5</td>
</tr>
<tr>
<td>FDA approved indication</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Number of patients enrolled</td>
<td>111 (101 pts infused)</td>
<td>111 (93 pts infused)</td>
<td>342 (268 pts infused)</td>
<td>74 (68 pts infused)</td>
<td>140</td>
</tr>
<tr>
<td>Lymphoma subtypes studied</td>
<td>DLBCL, PMBCL, tFL</td>
<td>DLBCL, tFL</td>
<td>DLBCL, tFL, FL grade 3B, tMZL, tCLL, PMBCL</td>
<td>Mantle cell lymphoma</td>
<td>FL =124, MZL =16</td>
</tr>
<tr>
<td>Co-stimulatory domain</td>
<td>CD28</td>
<td>4-1BB</td>
<td>4-1BB</td>
<td>CD28</td>
<td>CD28</td>
</tr>
<tr>
<td>Cell population</td>
<td>PMBC</td>
<td>PMBC</td>
<td>CD4+ and CD8+ T cells</td>
<td>PMBC without CD19+ cells</td>
<td>PMBC</td>
</tr>
<tr>
<td>Gene transfer system</td>
<td>Retrovirus</td>
<td>Lentivirus</td>
<td>Lentivirus</td>
<td>Retrovirus</td>
<td>Retrovirus</td>
</tr>
<tr>
<td>Bridging therapy</td>
<td>–</td>
<td>92% patient received</td>
<td>59% patients received</td>
<td>37% patients received</td>
<td>NA</td>
</tr>
<tr>
<td>Conditioning regimen</td>
<td>Cy/Flu</td>
<td>73% Cy/Flu, 20% Bendamustine</td>
<td>Cy/Flu</td>
<td>Cy/Flu</td>
<td>Cy/Flu</td>
</tr>
<tr>
<td>Median time from apharesis to CAR-T</td>
<td>17 days</td>
<td>54 days</td>
<td>24 days (Optimized subset)</td>
<td>16 days</td>
<td>NA</td>
</tr>
<tr>
<td>Best ORR</td>
<td>82% (CR 58%)</td>
<td>52% (CR 40%)</td>
<td>73% (CR 53%)</td>
<td>93% (CR 67%)</td>
<td>93% (CR 80%); FL: 95% (CR 81%); MZL: 81% (CR 75%)</td>
</tr>
<tr>
<td>Responses on follow up</td>
<td>42% (CR 40%) at 12 mts</td>
<td>34% (CR 29%) at 12 mts</td>
<td>47% (CR 41%) at 6 mts</td>
<td>57% ORR at 12 mts 68% ORR at 15 mts</td>
<td></td>
</tr>
<tr>
<td>Durability of responses</td>
<td>mPFS: 5.9 mts; mOS: 25.8 mts</td>
<td>18-month PFS: 67%; mOS: 11.1 mts</td>
<td>mPFS: 6.8 mts; mOS.9 mts</td>
<td>mPFS: 23.5 mts</td>
<td>mDOR: 20.8 mts; 12-month OS: 94%</td>
</tr>
<tr>
<td>CRS, grade 3 or higher, %</td>
<td>13% (Lee et al. Grading System)</td>
<td>22% (University of Pennsylvania Grading System)</td>
<td>2% (Lee et al. Grading System)</td>
<td>15% (Lee et al. Grading System)</td>
<td>11% (Lee et al. Grading System)</td>
</tr>
<tr>
<td>Neurotoxicity, grade 3 or higher, %</td>
<td>28%</td>
<td>12%</td>
<td>10%</td>
<td>31%</td>
<td>19%</td>
</tr>
</tbody>
</table>
is implicated in all stages of differentiation of B-cells, it is of particular interest in multiple myeloma. CAR T-cells targeting BCMA have been successful in phase 2 clinical trials with durable responses (31-34) (Table 4). A biologics license application has been sent to the FDA for the use of idecabtagene vicleucel (ide-cel) in patients with multiple myeloma who have received at least 3 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. Other well-known plasma cell markers are CD138 and CD38. However, they are not specific to plasma cells and raises the concern for safety with utilization of these markers as targets for CAR T-cell therapy. In a study of five patients using CD138-CAR T-cell therapy, no excess toxicities were seen (35). Further studies evaluating these and other targets are underway.

Current challenges in CAR T-cell therapy

Time from collection to infusion of CAR T-cells

The time from apheresis to CAR T-cell infusion ranges between 17 to 54 days depending on the manufacturing process of each product. Some patients may experience significant disease progression during this hiatus, necessitating administration of “bridging” therapy. In a US lymphoma CAR T-cell consortium study, patients who received bridging therapy before CAR T-cell infusion had a low response rate and higher adverse events than those who did not (36). These low response rates could be either due to aggressive underlying disease biology or due to the toxic effects of bridging therapy on CAR T-cells that are subsequently infused. Nonetheless, prolonged turnaround time limits the number of patients who can benefit from CAR T-cell therapy. There is a need to optimize the production process and reduce the manufacturing time (Figure 2). One method to reduce manufacturing time includes the development of allogeneic CAR T-cells or “off-the-shelf” CAR T-cells.

What are allogeneic CAR T-cells or “off-the-shelf” CAR T-cells, and how can they shorten the manufacturing time?

Since each CAR T-cell product is manufactured for an individual patient, it cannot be reused for other patients. It leads to an increase in cost, labor, and the time required to manufacture them. A possible solution is the development of allogeneic or “off-the-shelf” CAR T-cells, which can be used simultaneously for multiple patients. However, there are two significant concerns with the use of allogeneic CAR T-cells in its current iteration; life-threatening graft-versus-host disease (GVHD) and CAR T-cell rejection.
Both effects are due to the TCR in αβ T-cells, which recognize the peptides presented by MHC molecules, differentiating self-antigens from foreign antigens. One approach on developing allogeneic or “off-the-shelf” CAR T-cells is the use of non-αβ cells such as natural killer (NK) cells engineered with a CAR directed against the tumor antigen. Such CAR-transduced NK cells have successfully been developed from cord blood cells in CD19-positive lymphoid tumors (37). Another approach is the development of CAR T-cells with the deletion of the αβ TCR gene bypassing the MHC mismatch responses (38,39). ALLO-501 is one such anti-CD19 CAR T-cell product in which the TCR alpha constant gene is disrupted to reduce the risk of GVHD and the CD52 gene is disrupted to permit the use of ALLO-647, an anti-CD52 monoclonal antibody for prolonged host lymphodepletion (40). ALLO-501 in combination with ALLO-647 has shown promise in early phase studies in relapsed DLBCL and FL. Such allogeneic CAR T-cells with deleted TCR genes, however, pose unique problems, such as the need for alternative techniques for expansion of CAR T-cells and their lack of in-vivo persistence after infusion. These issues will need to be addressed before its use in clinical practice. There are multiple ongoing trials with preliminary safety and efficacy results using allogenic CAR T-cells (Table 5).

### Durability of responses after CAR T-cell therapy

The best ORR observed with CAR-T cell therapy for DLBCL ranges between 50% to 80% (Table 1). However, most of these responses taper off over a few months, with up to half of the responders relapsing on long-term follow-up. CAR T-cell antigen positive relapses observed after CAR T-cell therapy have been attributed to the lack of T-cell expansion after infusion, lack of persistence of CAR-T cells, and CAR-T cell anergy. Different CAR T-cell constructs used in different clinical trials prevent direct comparisons of efficacy, however, correlative studies suggest T-cell expansion and persistence after infusion is critical for achieving an effective clearance of the cancer (41). The fate of CAR T-cells after infusion is dependent on several factors related to CAR T-cell construct such as type of costimulatory molecules used, type of CAR antibody used, the T-cell phenotype used for manufacturing of CAR T-cells and the expression of T-cell exhaustion markers by the tumor cells leading to T-cell anergy.

### How can we improve T-cell expansion and persistence?

CD28 co-stimulation is required for clonal expansion of activated T cells and form effector memory T-cells, whereas the 4-1BB co-stimulation is associated with long-term survival of T cells (42). In preclinical studies, the presence...
**Table 4** Phase 2 trials of anti-BCMA CAR T-cell therapy in multiple myeloma

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Orvaccabtagene Autoleucel (32)</th>
<th>Idecabtagene Vicleucel (33)</th>
<th>JNJ-4528 (31)</th>
<th>LCAR-B38M (34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial</td>
<td>EVOLVE</td>
<td>KarMMa</td>
<td>CARTITUDE-1</td>
<td>LEGEND-2</td>
</tr>
<tr>
<td>Number of patients</td>
<td>100</td>
<td>140</td>
<td>29</td>
<td>57</td>
</tr>
<tr>
<td>Patients studied</td>
<td>MM relapsed to more than 3 lines of therapy*</td>
<td>MM relapsed to more than 3 lines of therapy*</td>
<td>MM relapsed to more than 3 lines of therapy*</td>
<td>MM relapsed to more than 3 lines of therapy*</td>
</tr>
<tr>
<td>Co-stimulatory domain</td>
<td>4-1BB</td>
<td>4-1BB</td>
<td>4-1BB</td>
<td>4-1BB</td>
</tr>
<tr>
<td>Conditioning regimen</td>
<td>Cy/Flu</td>
<td>Cy/Flu</td>
<td>Cy/Flu</td>
<td>Cy alone</td>
</tr>
<tr>
<td>Responses at recent update</td>
<td>At all dose levels</td>
<td>At all dose levels</td>
<td>At all dose levels</td>
<td>At all dose levels</td>
</tr>
<tr>
<td></td>
<td>• ORR: 40/44 (91%)</td>
<td>• ORR: 94/128 (73%)</td>
<td>• ORR: 29/29 (100%)</td>
<td>• ORR: 50/57 (88%)</td>
</tr>
<tr>
<td></td>
<td>• sCR: 40/128 (31%)</td>
<td>• sCR: 22/29 (76%)</td>
<td>• VGPR: 6/29 (21%)</td>
<td>• sCR: 42/57 (74%)</td>
</tr>
<tr>
<td></td>
<td>• PR: 12/44 (27%)</td>
<td>• VGPR: 11/44 (25%)</td>
<td>• PR: 6/57 (11%)</td>
<td>• VGPR: 2/57 (4%)</td>
</tr>
<tr>
<td>Long-term follow-up</td>
<td>mPFS not reached after 5.9 mts of median follow-up</td>
<td>mPFS of 8.6 mts; mDOR of 10.6 mts</td>
<td>PFS at 6 mts: 93%</td>
<td>mPFS of 20 mts; mDOR of 22 mts; OS at 18 mts: 68%; PFS at 18 mts: 50%</td>
</tr>
<tr>
<td>CRS, grade 3 or higher, %</td>
<td>1/51 (2%)</td>
<td>7/128 (5%)</td>
<td>2/29 (7%)</td>
<td>4/57 (7%)</td>
</tr>
<tr>
<td>Neurotoxicity, grade 3 or higher, %</td>
<td>2/51 (4%)</td>
<td>4/128 (3%)</td>
<td>1/29 (3%)</td>
<td>1/57 (2%)</td>
</tr>
</tbody>
</table>

*, should have received immunomodulatory drug (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody. CR, complete response; sCR, stringent complete response; ORR, overall response rate; VGPR, very good partial response; PR, partial response; mPFS, median progression-free survival; mDOR, median duration of response; OS, overall survival; mts, months; CRS, cytokine release syndrome; pts, patients; MM, multiple myeloma; Cy/Flu, cyclophosphamide and fludarabine.

of a 4-1BB costimulatory domain resulted in greater T-cell persistence and antitumor activity compared to the CD28 domain (43). A clinical study comparing, anti-CD19 CAR T-cell with a CD28 co-stimulatory domain versus an anti-CD19 CAR T-cell with a 4-1BB costimulatory in relapsed or refractory B-cell NHL manufactured under similar conditions, showed similar anti-tumor efficacy however, with longer persistence of the CAR T-cell with the 4-1BB co-stimulatory domain (44). After the success of second-generation CAR T-cell constructs in clinical trials, the development of newer constructs is ongoing. Third-generation CAR T-cells consist of two costimulatory molecules. The most common co-stimulatory domains used in third-generation CAR T-cells include CD28 and 4-1BB with early trials demonstrating safety and efficacy (45,46). Fourth-generation CAR T-cells contain a cytokine secreting domain in addition to the costimulatory molecules to promote an immune favorable tumor microenvironment. They are also known as T-cells redirected for universal cytokine-mediated killing (TRUCKs). This strategy is to boost T-cell anti-tumor effects with the help of several cytokines. As these cytokines may exhibit systemic toxicity, with localized delivery of the cytokines we hope to limit systemic adverse events. The studies with fourth-generation CAR T-cells are mostly preclinical and in solid tumors (47). A T-cell mediated response directed at epitopes targeted
by murine anti-CD19 scFv leads to decreased persistence of CAR-T cells (48). A newer CAR design with humanized scFv has shown reduced CAR T-cell antigenicity and improved efficacy in B-ALL patients who have relapsed after murine based CD19 CAR T-cell therapy (49). The hope, with these newer designs, is to allow more significant T-cell expansion and persistence.

The T-cell phenotype used for adoptive cell therapy influences the persistence and expansion of CAR T-cells. In the ZUMA-1 and JULIET trials, patients received T-cell products comprising random compositions of CD4+ and CD8+ naive and memory T cells. The antigen-specific CD4+ and CD8+ naive and memory T cells have a synergistic effect on tumor efficacy (50). These variations in T-cell composition may amount to a difference in response rates amongst these trials. Adoptive transfer of defined CD4+ and CD8+ T-cell ratios show clear benefits with synergistic effect on tumor efficacy; however, achieving a desirable proportion of CD4+ and CD8+ T-cells in lymphoid malignancies can be challenging due to prior lymphocyte toxic chemotherapy. Due to extensive cell selection, the costs and processing time increase with an overall lowered CAR T-cell product. Newer cell processing instruments such as the CliniMACS® Prodigy (Miltenyi Biotec, Inc.) systems allow the enrichment of specific subsets of T cells, such as CD4+, CD8+, CD25+, or CD62L+ T cells with the generation of CAR T-cell within 14 days, significantly shortening the time required (51). Lisocabtagene maraleucel in the Transcend NHL 001 trial utilized CD4+and CD8+ T-cells with a median manufacturing time of 24-days, indicating the feasibility of such an approach (52).

CAR T-cell infusion has shown to increase the expression of immune checkpoints on the tumor cells. Immune checkpoints are regulatory molecules that prevent effective activation of the immune system for antitumor efficacy.

Tumor cells overexpress PD-L1, which interacts with PD-1 present on the T-cells leading to T-cell anergy. Such an increase in PD-1 expression has been seen in tissues samples of B-cell malignancy patients treated with CD19 CAR T-cells (53). Checkpoint inhibitors such as pembrolizumab have been used to increase CAR T-cell persistence (54). In an early phase trial (ZUMA-6), a PD-L1 inhibitor atezolizumab was used in combination with axi-cel (55). The trial demonstrated a manageable safety profile with a more than two-fold increase in CAR T-cell expansion compared to infusion with axi-cel alone, as in the ZUMA-1 trial. Similar results were also seen with the combination of durvalumab, another PD-L1 inhibitor, and liso-cel (56). There an ongoing phase I/II trial of pembrolizumab and tisa-cel [NCT02650999]. Other approaches involve utilizing intrinsic blockade of PD-1 signaling and knockout or knockdown of the PD-1 receptor (57).

Another strategy is to use surface receptors to modify the tumor microenvironment. The blockage of PD1-PDL1 axis by generation of CAR T-cell with a dominant-negative PD1 molecule on its surface has shown promising results in relapsed and refractory B-cell malignancies (58). This combinational approach of overcoming T-cell exhaustion is synergistic and shows promise. There is a concern for an increased incidence of immune-related toxicities with this approach due to the overstimulation of the CAR T-cell.
<table>
<thead>
<tr>
<th>Grade</th>
<th>Lee criteria</th>
<th>Penn criteria</th>
<th>CARTOX criteria</th>
<th>ASTCT criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>Symptoms are not life-threatening and require symptomatic treatment only (fever, nausea, fatigue, headache, myalgias, malaise)</td>
<td>Mild reaction: • Treated with supportive care, such as antipyretics, antiemetics</td>
<td>• Temperature ≥38 °C • Grade 1 organ toxicity²</td>
<td>Fever: temperature ≥38 °C WITH • Hypotension: none AND/OR • Hypoxia: none</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 2</td>
<td>Symptoms require and respond to moderate intervention:</td>
<td>Moderate reaction: • Some signs of organ dysfunction¹ (grade 2 creatinine or grade 3 LFTs) related to CRS and not attributable to any other condition</td>
<td>• Hypotension responds to i.v. fluids or low-dose vasopressor • Hypoxia requiring FiO₂ &lt;40%</td>
<td>Fever: temperature ≥38 °C WITH Hypoxia: not requiring vasopressors AND/OR</td>
</tr>
<tr>
<td></td>
<td>• Oxygen requirement &lt;40% FiO₂ OR • Hypotension responsive to i.v. fluids or • Low dose of one vasopressor OR Grade 2 organ toxicity¹</td>
<td></td>
<td></td>
<td>Hypoxia: requiring low-flow nasal cannula or blow-by</td>
</tr>
<tr>
<td>Grade 3</td>
<td>Symptoms require and respond to aggressive intervention:</td>
<td>More severe reaction: • Hospitalization for management of CRS-related symptoms, including neutropenic fever and need for i.v. therapies (not including fluid resuscitation for hypotension)</td>
<td>• Hypotension needing high-dose or multiple vasopressors • Hypoxia requiring FiO₂ ≥40% • Grade 3 organ toxicity² or grade 4 transaminitis</td>
<td>• Fever: temperature ≥38 °C WITH Hypoxia: requiring a vasopressor</td>
</tr>
<tr>
<td></td>
<td>• Oxygen requirement ≥40% FiO₂ OR • Hypotension requiring high-dose or multiple vasopressors OR • Grade 3 organ toxicity¹ or grade 4 transaminitis</td>
<td>• Hypotension treated with multiple fluid boluses or low-dose vasopressors</td>
<td></td>
<td>WITH Hypoxia: requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask</td>
</tr>
<tr>
<td></td>
<td>• Coagulopathy requiring fresh frozen plasma, cryoprecipitate, or fibrinogen concentrate • Hypoxia requiring supplemental oxygen (nasal cannula oxygen, high-flow oxygen, CPAP, or BiPAP)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 5 (continued)
This needs to be evaluated in larger studies before future applications in the clinics.

**Relapses or resistance to CAR T-cell therapy**

Despite good initial response, relapses do occur after CAR T-cell therapy. Most of the relapses are due to lack of persistence of CAR T-cells as mentioned above, however a few also develop a CAR T-cell antigen negative relapse. Antigen negative relapses are seen due to antigen escape by a mutation in the antigen expressing gene. This has most extensively been studied with CD19 expressing malignancies and occurs in about one fourth of the relapses (59,60). Another observed reason for antigen negative relapses is due to CAR T-cell-mediated trogocytosis. Trogocytosis is a process in which the target antigen is transferred to T cells, thereby decreasing target density on tumor cells and abating T cell activity by promoting fratricide T cell killing and T cell exhaustion (61).

**How can we overcome resistance to CAR T-cells?**

Targeting of a single tumor antigen such as CD19 by CAR T-cells leads to selection pressure amongst rapidly proliferating CD19+ malignant tumor cells. Subsequently, genetic mutations occur, leading to the downregulation of CD19 and, consequently, CD19 negative relapses (59,60). CAR T-cells targeting two or more antigens can decrease the development of such mutations and, subsequently, antigen-negative relapses. Multi-target CAR T-cell therapy can be achieved by using bicistronic CAR T-cells, tandem CAR T-cells, pooled mixture of CAR T-cells targeting two different targets or by co-transduction of CAR T-cells with two separate gene vectors (Figure 3). Bicistronic CAR T-cells use bicistronic vectors that encode two different CARs on the same cells. A bicistronic CAR T-cell targeting CD19 and CD22 has been successfully developed and studied in early phase clinical trials in relapsed and refractory DLBCL with a manageable safety profile (62). Tandem CAR T-cells is one in which a single CAR T-cell has two different antigen-recognizing epitopes on the same receptor. Another strategy is the development of T-cells with universal CARs, which can target multiple tumor-associated antigens (TAA) simultaneously and at different concentrations.

**What are universal CARs, and how can they improve tumor specificity?**

Universal CARs are a type of engineered CAR T-cells with CARs designed to recognize different tumor antigens in vivo without the need for manufacturing antigen-specific CARs. They allow expanding the spectrum of antigens that can be targeted by the same CAR T-cell. Universal CARs separate the antigen-binding domain from the T-cell body, permitting the same T-cell body to target different antigens. It allows targeting multiple TAA simultaneously. Since tumor cells in different patients with the same malignancy have variable expressions of TAA, the manufacturing of these universal CARs will allow better tumor specificity. The two systems currently in
development include the biotin-binding immune receptor (BBIR) CAR and the split, universal and programmable (SUPRA) CAR system (63-65). Both systems use an antigen recognizing molecule and a genetically engineered T-cell that can bind to these molecules. The BBIR CAR system uses a biotinylated antigen-specific molecule, which tags tumor antigen containing tumor cells for recognition by the biotin-binding T-cell with an extracellular avidin domain (Figure 4A). The SUPRA CAR system uses an scFv fused to a cognate leucine zipper (zipFv) and a T-cell with a leucine zipper as its extracellular domain (zipCAR). The zipFV tags tumor antigens with its scFv and provides a binding site for the zipCAR via leucine zipper adaptor molecules (Figure 4B). Both these systems are still in their early stages of development; however, they provide a glimpse into the future of patient-specific therapy.

**Toxicities with CAR-T cell therapy**

Although quite promising, CAR T-cell therapy can lead to severe toxicities. Most significant among them are the cytokine release syndrome (CRS) and neurotoxicity. CRS is presumably due to activation of the immune system by proliferating CAR T-cells with the recruitment of other T-cells. The hyperactive immune system leads to the release of pro-inflammatory cytokines such as interleukin-6 (IL-6), IL-10, interferon-γ, and granulocyte-macrophage stimulating factor (66). Clinically, CRS manifests as fever, fatigue, malaise, nausea, tachycardia, hypotension, capillary leak syndrome, and end-organ damage. The severity of CRS was graded based on various criteria in the past, but now, American Society for Transplantation and Cellular Therapy (ASTCT) recommends the use of ASTCT consensus criteria for grading of CRS (Table 5) (67).

Most patients with grade 1 CRS are managed with supportive care, whereas higher grades of CRS require the administration of interleukin-6 antagonist, tocilizumab. Neurotoxicity is the second most common adverse event with CAR T-cell therapy, which is now termed as immune effector cells-associated neurotoxicity syndrome (ICANS). The pathophysiology of ICANS is less well understood. It manifests clinically as toxic encephalopathy with confusion, word-finding difficulty, and aphasia, but it can seldom progress to more severe forms with coma, seizures, motor weakness, and cerebral edema. The frequency of severe CRS and ICANS ranges from 10% to 30% for different CAR T-cell constructs. It continues to be one of the significant limitations requiring inpatient monitoring.
In addition to CRS and neurotoxicity, off-target effects are observed, resulting in B-cell aplasia and hypogammaglobulinemia. B-cell aplasia leads to long term increased risk of infection and dependence on intravenous gammaglobulin infusions.

The risk of severe CRS and ICANS with CAR-T cell therapy is high. Intensive inpatient monitoring is required with the availability of neurology consultants and the intensive care unit. Currently, the IL-6 antagonist, tocilizumab, is the most widely used medication in the event of severe CRS and is required to be available for emergent administration. These requirements limit the use of CAR T-cell therapy to specialized medical centers. Outpatient administration of liso-cel was studied due to late-onset and lower incidence of toxicities (68). In this study, there were no deaths, and the efficacy was comparable to the general population who received liso-cel therapy inpatient. However, patients were highly selected with strict requirements for monitoring and may not apply to the general population who receive their care away from an academic/specialized tertiary center.

Not all patients develop life threatening CRS with CAR T-cell therapy. Therefore, predictive biomarkers for early identification of patients who might develop grade 3 or higher CRS is required. The predictive utility of biomarkers, such as high serum levels of c-reactive protein (CRP), ferritin, IL-6, IL-10, IFN-γ, and IL-15 vary and depend upon the type of CAR T-cell product used (15) (48,69-71). We are yet to successfully identify a biomarker with high predictive capacity. Another strategy is the early administration of corticosteroids and the IL-6 antagonist, tocilizumab, to reduce to the severity of CRS and ICANS. This was studied in cohort 4 of the ZUMA-1 trial (72). In this early intervention cohort, only two percent of patients experienced grade ≥3 CRS, and 17% experienced grade ≥3 neurological events compared to 13% and 28%, respectively, in the non-early intervention group. The overall response rate and duration of response were similar between the groups suggesting the possibility of early intervention without compromising efficacy. Our experience with early recognition and management of CRS and ICANS is improving with a higher proportion of patients treated with adoptive T-cell therapy. A composite approach of outpatient therapy, early identification of patients with risk of severe adverse events, and early administration of corticosteroids and tocilizumab may allow CAR T-cell therapy to be safely administered in community hospitals. It will subsequently expand access to CAR T-cell therapy to the general population.

**Costs with CAR T-cell therapy**

In the United States, single treatment with Yescarta® (axi-cel) costs around USD 373,000, whereas Kymriah® (tisa-cel) costs about USD 475,000 per patient. The individualized nature of therapy, complexity, and labor-intensive manufacturing are few reasons provided by the manufacturers to explain such expensive price tags. These costs do not include hospital stay, medications toxicity management, and supportive care, which could amount
to a total of around USD 750,000 to 1,000,000. The reimbursement of CAR T-cell therapy by payers may not include coverage of the overhead costs incurred by the hospital. Therefore, very few centers in the United States are currently able to provide CAR T-cell therapy for patients. If CAR T-cell therapy moves to the second line setting in DLBCL and gets approved in other lymphoid malignancies, the total healthcare costs would likely be much higher. The hope is, in the future, the combination of “off-the-shelf” CAR T-cells with universal CAR T-cells will significantly lower the cost while improving its efficacy.

Future directions

There is no doubt that the advent of CAR-T cell therapies has revolutionized the care of patients with various lymphoid neoplasms. The median overall survival in the ZUMA-1 study of relapsed/refractory DLBCL after failure of at least 2 lines of therapy was not reached at 28-month follow-up, which is an unprecedented outcome in an otherwise uniformly fatal situation. Given these results, CAR T-cell therapy is now being evaluated in comparison with autologous stem cell transplant approach among DLBCL patients who relapse after first line therapy (ZUMA-7 trial; NCT03391466). It is likely that CAR T-cell therapy will see more approvals in the near future, thereby leading to increasing number of eligible patients. However, given the intensive monitoring and personnel training required, the administration of CAR T-cell therapy is limited to select tertiary centers in the US and the world. In the long-term follow-up of ZUMA-1 trial, approximately 50% of patients who initially responded lost their response at longer follow-up. Similarly, the median overall survival in JULIET study was 11.5 months, but was not reached at median follow-up of 19 months among patients who achieved a CR. These findings underscore the need to conduct further research for better patient selection to optimize CAR T-cell treatments. As CAR T-cell therapy gets approved for more indications, payer reimbursements will become unsustainable at the prevailing costs. Although the initial high cost can be attributed to research and development expenditures, the cost of subsequent expansion of CAR T-cell products may be lower and prices may need to be re-negotiated down the road. As future research is being conducted into improving the CAR T-cell treatments, a major focus should be the mitigation of physical and financial toxicities, so most eligible patients can have easy access to therapy at a center near them.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Umang Swami and Mohammed M. Milhem) for the series “Cancer Immunotherapy: Recent Advances and Challenges” published in *Annals of Translational Medicine*. The article has undergone external peer review.

Peer Review File: Available at http://dx.doi.org/10.21037/atm-20-5546

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-5546). The series “Cancer Immunotherapy: Recent Advances and Challenges” was commissioned by the editorial office without any funding or sponsorship. Dr. SMA reports that he receives research funding (to his institution for clinical trials) from Bristol Myers Squibb, Affimed, Seattle Genetics, Regeneron, Al Therapeutics, Trillium and ADC Therapeutics. Dr. AM reports that he receives research funding from Incyte, Takeda, Fortyseven Inc./Gilead, Juno pharmaceuticals/Bristol Myers Squibb, Celgene/Bristol Myers Squibb, Oncotartis, Innate pharmaceuticals, Seattle Genetics, TG Therapeutics, Affimed, Merck, Kite/Gilead, Roche-Genentech, ADC therapeutics, Miragen, Rhizen Pharmaceuticals, and consultancy/speaker bureau fees from Gilead, Astra Zeneca, Pharmacies, Seattle Genetics, Incyte, Morphosys-Incyte, TG Therapeutics, Carevive, Kyowa Kirin, Rigel pharmaceuticals. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the
References


43. Zhao Z, Condomines M, van der Stegen Sjoukje JC, et al. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of


